In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 56 for your search:

Cancer Type/Condition:  Breast cancer, female
Trial Type:  Prevention
Trial Status:  Closed
Sponsor of Trial:  NCI

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]

Phase: Phase III, Phase II
Type: Diagnostic, Prevention
Status: Completed
Age: 18 to 30
Sponsor: NCI, Other
Protocol IDs: CDR0000511819, U54CA116849, UMN-0505M69867, NCT00393172

Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study

Phase: Phase III
Type: Prevention, Treatment
Status: Closed
Age: 18 to 70 at time of diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000066920, UCSD-980919, UCSD-WHEL, NCI-G99-1508, NCT00003787

Phase III Randomized Study of the Effects of Dietary Soy on Estrogens in Breast Fluid, Serum, and Urine Samples From Healthy Women. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 30 to 45
Sponsor: NCI
Protocol IDs: UHM-CHS-4116, CHS 14116, NCT00513916

Women's Health Initiative (WHI)

Phase: Phase III
Type: Health services research, Natural history/Epidemiology, Prevention
Status: Completed
Age: 50 to 79
Sponsor: NCI, NHLBI
Protocol IDs: 114, NCT00000611

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Phase: Phase III
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065314, CALGB-49901, S9630, U10CA037429, U10CA032102, SWOG-S9630, SWOG-9630, NCT00002920

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Phase: Phase III
Type: Prevention
Status: Completed
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: NSABP P-2, CDR0000067081, NCT00003906

Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women

Phase: Phase III
Type: Prevention
Status: Closed
Age: 55 and over
Sponsor: NCI, Other
Protocol IDs: CAPS08-15024, NCT01052051

Phase II Study of DiFluoroMethylOrnithine (DFMO) in Breast Dysplasia with Biomarker Abnormalities (Summary Last Modified 05/1999)

Phase: Phase II
Type: Prevention
Status: Closed
Age: 30-55 with exceptions
Sponsor: NCI
Protocol IDs: KUMC-HSC-6916-96, NCI-P97-0080

Phase II Randomized, Double Blind, Placebo-Controlled Study of Eflornithine (DFMO) in Women with Breast Neoplasia (Summary Last Modified 03/98)

Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UAB-9509, NCI-P97-0082

10.

Phase II Trial of Dietary Fatty Acids: Roles in Hormonally Mediated Cancers in Normal Premenopausal Women (Summary Last Modified 06/98)

Phase: Phase II
Type: Prevention
Status: Closed
Age: 18-35
Sponsor: NCI
Protocol IDs: UMN-9509M10234, NCI-P97-0108

11.

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

Phase: Phase II
Type: Prevention
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: ID94-029, P30CA016672, MDA-ID-94029, NCI-P97-0113, CDR0000065829, NCT00003099

12.

Raloxifene in Preventing Breast Cancer in Premenopausal Women

Phase: Phase II
Type: Prevention
Status: Completed
Age: 23 to 47
Sponsor: NCI
Protocol IDs: CDR0000066428, NCI-98-C-0123, MB-402, NCT00019500

13.

Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease

Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247

14.

Phase II Chemoprevention Study of Celecoxib in Premenopausal Women at High Risk For Estrogen Receptor-Negative Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Prevention
Status: Completed
Age: 18 to 55
Sponsor: NCI
Protocol IDs: KUMC-HSC-8919-02, NCT00056082

15.

Phase II Randomized Study of Tamoxifen and Fenretinide for the Prevention of Breast Cancer

Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CNR-IEO-007, U01-CA77188-01

16.

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: 040044, 04-C-0044, NCT00073073

17.

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Phase: Phase II
Type: Prevention
Status: Completed
Age: 21 to 48
Sponsor: NCI, Other
Protocol IDs: 02164, P30CA033572, CHNMC-IRB-02164, CDR0000355156, NCI-2011-00975, NCT00080756

18.

Letrozole in Preventing Breast Cancer in Postmenopausal Women

Phase: Phase II
Type: Prevention
Status: Completed
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000375585, DFCI-00024, UCLA-0210012-02, NCT00090857

19.

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE-CCF-4713, P30CA043703, NCT00253539

20.

Soy Isoflavones and Breast Cancer Risk Reduction

Phase: Phase II
Type: Prevention
Status: Closed
Age: 30 to 42
Sponsor: NCI, Other
Protocol IDs: 03-260, UTMB GCRC #635, R01CA095545, M01RR000073, 1UL1RR029876-01, NCT00204490

21.

Simvastatin in Preventing a New Breast Cancer in Women Who Are at High Risk for a New Breast Cancer After Undergoing Surgery for Ductal Carcinoma in Situ or Stage I, Stage II, or Stage III Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: JHOC-J0485, CDR0000477214, P50CA088843, P30CA006973, JHOC-J0485, JHOC-SKCCC-J0485, JHOC-04100404, J0485, NCT00334542

22.

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: J05100, CDR0000485361, P30CA006973, JHOC-J05100, JHOC-SKCCC-J05100, J05100, NCT00354640

23.

Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer

Phase: Phase II
Type: Prevention
Status: Closed
Age: 25 and older
Sponsor: NCI, Other
Protocol IDs: NCI 04B3, NWU03-1-04, NU-NWU03-1-04, NU-NCI-04B3, NU-0835-030, NCT00290758

24.

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067918, KUMC-HSC-7264-97, NCI-P00-0146, NCT00005879

25.

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

Phase: Phase II
Type: Prevention
Status: Closed
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000393444, UTSMC-0799-302, UTSMC-8843, N01-CN-95139, NCT00096369

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map